clnn20240331c_10q.htm
0001822791 Clene Inc. false --12-31 Q1 2024 0.0001 0.0001 300,000,000 300,000,000 128,433,721 128,433,721 128,422,851 128,422,851 20 30 3 20 30 5 5 0 0 10 10 7 10 7 5 27 334 15,000 12 12 96.22 103.24 3.38 3.98 5.00 6.08 0 4.28 5.38 3.88 5.03 100.00 105.00 100.00 110.00 4.55 5.15 4.13 4.74 0.83 2.21 1.08 2.46 97.50 4.70 1.75 300,000,000 0.0001 1,000,000 0.0001 128,433,721 128,422,851 0 0 0 0 0.5 0 0 0.5 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 5 false false false false Represents 2,407,500 shares of Common Stock underlying warrants to purchase one-half (1/2) of one share of Common Stock, issued during Tottenham’s initial public offering. We may redeem the outstanding warrants at $0.01 per warrant if the last sales price of our Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period. As of March 31, 2024 and December 31, 2023, no warrants had been exercised. Represents 50,000,000 shares of Common Stock underlying the Tranche A Warrants to purchase one share of Common Stock, issued in our June 2023 public equity offering. As of March 31, 2024 and December 31, 2023, no warrants had been exercised. Represents 50,000,000 shares of Common Stock underlying the Tranche B Warrants to purchase one share of Common Stock, issued in our June 2023 public equity offering. As of March 31, 2024 and December 31, 2023, no warrants had been exercised. Represents 3,000,000 shares of Common Stock underlying the New Avenue Warrant, issued pursuant to the Second Amendment (see Note 8). As of March 31, 2024 and December 31, 2023, the warrant had not been exercised. Represents 24,583 shares of Common Stock underlying warrants to purchase one-half (1/2) of one share of Common Stock, issued to the financial advisor and lead underwriter of Tottenham’s initial public offering upon their exercise of a unit purchase option in July 2021. As of March 31, 2024 and December 31, 2023, no warrants had been exercised. 00018227912024-01-012024-03-31 0001822791us-gaap:CommonStockMember2024-01-012024-03-31 0001822791us-gaap:WarrantMember2024-01-012024-03-31 xbrli:shares 00018227912024-05-06 thunderdome:item iso4217:USD 00018227912024-03-31 00018227912023-12-31 iso4217:USDxbrli:shares 0001822791us-gaap:ProductMember2024-01-012024-03-31 0001822791us-gaap:ProductMember2023-01-012023-03-31 0001822791us-gaap:RoyaltyMember2024-01-012024-03-31 0001822791us-gaap:RoyaltyMember2023-01-012023-03-31 00018227912023-01-012023-03-31 0001822791us-gaap:CommonStockMember2023-12-31 0001822791us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001822791us-gaap:RetainedEarningsMember2023-12-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0001822791us-gaap:CommonStockMember2024-01-012024-03-31 0001822791us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0001822791us-gaap:RetainedEarningsMember2024-01-012024-03-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-31 0001822791us-gaap:CommonStockMember2024-03-31 0001822791us-gaap:AdditionalPaidInCapitalMember2024-03-31 0001822791us-gaap:RetainedEarningsMember2024-03-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-31 0001822791us-gaap:CommonStockMember2022-12-31 0001822791us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001822791us-gaap:RetainedEarningsMember2022-12-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 00018227912022-12-31 0001822791us-gaap:CommonStockMember2023-01-012023-03-31 0001822791us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0001822791us-gaap:RetainedEarningsMember2023-01-012023-03-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-31 0001822791us-gaap:CommonStockMember2023-03-31 0001822791us-gaap:AdditionalPaidInCapitalMember2023-03-31 0001822791us-gaap:RetainedEarningsMember2023-03-31 0001822791us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-31 00018227912023-03-31 00018227912020-12-30 00018227912023-01-012023-12-31 utr:Y 0001822791us-gaap:EquipmentMembersrt:MinimumMember2024-03-31 0001822791us-gaap:EquipmentMembersrt:MaximumMember2024-03-31 0001822791us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2024-03-31 0001822791us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2024-03-31 0001822791us-gaap:ComputerEquipmentMembersrt:MinimumMember2024-03-31 0001822791us-gaap:ComputerEquipmentMembersrt:MaximumMember2024-03-31 0001822791clnn:ReverseRecapitalizationMemberclnn:CleneNanomedicineContingentEarnoutMember2024-03-31 utr:D 0001822791clnn:ReverseRecapitalizationMemberclnn:CleneNanomedicineContingentEarnoutMember2024-01-012024-03-31 0001822791clnn:ReverseRecapitalizationMemberclnn:InitialStockholdersContingentEarnoutMember2024-03-31 0001822791clnn:GrantFundingOnConditionalGrantsMember2024-01-012024-03-31 0001822791clnn:GrantFundingOnConditionalGrantsMember2023-01-012023-03-31 0001822791us-gaap:USTreasurySecuritiesMember2024-03-31 0001822791us-gaap:MoneyMarketFundsMember2024-03-31 0001822791us-gaap:CashEquivalentsMember2024-03-31 0001822791us-gaap:CashMember2024-03-31 0001822791us-gaap:CashAndCashEquivalentsMember2024-03-31 0001822791clnn:UsTreasurySecuritiesWithMaturityGreaterThan90DaysButLessThan1YearMember2024-03-31 0001822791clnn:MarketableSecuritiesMember2024-03-31 0001822791us-gaap:USTreasurySecuritiesMember2023-12-31 0001822791us-gaap:MoneyMarketFundsMember2023-12-31 0001822791us-gaap:CashEquivalentsMember2023-12-31 0001822791us-gaap:CashMember2023-12-31 0001822791us-gaap:CashAndCashEquivalentsMember2023-12-31 0001822791clnn:UsTreasurySecuritiesWithMaturityGreaterThan90DaysButLessThan1YearMember2023-12-31 0001822791clnn:MarketableSecuritiesMember2023-12-31 0001822791us-gaap:EquipmentMember2024-03-31 0001822791us-gaap:EquipmentMember2023-12-31 0001822791us-gaap:OfficeEquipmentMember2024-03-31 0001822791us-gaap:OfficeEquipmentMember2023-12-31 0001822791us-gaap:ComputerEquipmentMember2024-03-31 0001822791us-gaap:ComputerEquipmentMember2023-12-31 0001822791us-gaap:LeaseholdImprovementsMember2024-03-31 0001822791us-gaap:LeaseholdImprovementsMember2023-12-31 0001822791us-gaap:ConstructionInProgressMember2024-03-31 0001822791us-gaap:ConstructionInProgressMember2023-12-31 0001822791us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-31 0001822791us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-31 0001822791us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-31 0001822791us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-31 xbrli:pure 0001822791clnn:LeaseForLaboratorySpaceMember2021-09-30 0001822791clnn:LeaseForLaboratorySpaceMember2021-09-012021-09-30 0001822791clnn:LeaseForLaboratorySpaceMember2022-02-28 0001822791clnn:LeaseForLaboratorySpaceMember2022-02-012022-02-28 0001822791clnn:LeaseForLaboratorySpaceMember2022-09-30 0001822791clnn:LeaseForLaboratorySpaceMember2022-09-012022-09-30 0001822791clnn:The2019CecilLoanMemberclnn:NotesPayableMember2024-03-31 0001822791clnn:The2019CecilLoanMemberclnn:NotesPayableMember2023-12-31 0001822791clnn:The2019MarylandDhcdMemberclnn:NotesPayableMember2024-03-31 0001822791clnn:The2019MarylandDhcdMemberclnn:NotesPayableMember2023-12-31 0001822791clnn:The2022MarylandDhcdMemberclnn:NotesPayableMember2024-03-31 0001822791clnn:The2022MarylandDhcdMemberclnn:NotesPayableMember2023-12-31 0001822791clnn:AvenueMemberclnn:NotesPayableMember2024-03-31 0001822791clnn:AvenueMemberclnn:NotesPayableMember2023-12-31 0001822791clnn:NotesPayableMember2024-03-31 0001822791clnn:NotesPayableMember2023-12-31 0001822791clnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2024-03-31 0001822791clnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2023-12-31 0001822791clnn:The2022DhcdLoanMemberus-gaap:ConvertibleNotesPayableMember2024-03-31 0001822791clnn:The2022DhcdLoanMemberus-gaap:ConvertibleNotesPayableMember2023-12-31 0001822791us-gaap:ConvertibleNotesPayableMember2024-03-31 0001822791us-gaap:ConvertibleNotesPayableMember2023-12-31 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2019-02-28 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2019-02-282019-02-28 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2024-01-012024-03-31 0001822791clnn:The2019MDLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-01-012023-03-31 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2019-04-30 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2019-04-302019-04-30 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2024-01-012024-03-31 0001822791clnn:The2019CecilLoanMemberclnn:AdvanceCecilIncMember2023-01-012023-03-31 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-05-31 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2024-01-012024-03-31 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-05-012022-05-31 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2024-03-31 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-12-31 0001822791clnn:The2022MdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-01-012023-03-31 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-12-31 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2024-03-31 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-12-31 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2022-12-012022-12-31 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2024-01-012024-03-31 0001822791clnn:The2022DhcdLoanMemberclnn:DepartmentOfHousingAndCommunityDevelopmentMember2023-01-012023-03-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2021-05-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2021-05-012021-05-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2024-01-012024-03-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2023-10-012023-12-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberclnn:NotesPayableTranche1Member2021-05-012021-05-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberclnn:NotesPayableTranche1Member2021-09-012021-09-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberclnn:NotesPayableTranche2Member2021-05-31 utr:M 0001822791clnn:AvenueMembersrt:MinimumMemberclnn:PublicEquityOfferingMember2023-06-012023-06-30 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2024-03-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2024-03-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2023-12-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2024-01-012024-03-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMemberus-gaap:ConvertibleNotesPayableMember2023-01-012023-03-31 0001822791clnn:The2021AvenueLoanMemberclnn:AvenueMember2023-01-012023-03-31 0001822791clnn:WarrantsIssuedWith2021AvenueLoanMemberclnn:AvenueMember2021-05-31 0001822791clnn:NewAvenueWarrantMemberclnn:AvenueMember2021-05-31 0001822791clnn:The2019MDLoanMemberclnn:NotesPayableMember2024-03-31 0001822791clnn:The2021AvenueLoanMemberclnn:NotesPayableMember2024-03-31 0001822791clnn:The2022MdLoanMemberclnn:NotesPayableMember2024-03-31 0001822791clnn:The2022DhcdLoanMemberclnn:NotesPayableMember2024-03-31 0001822791us-gaap:CapitalAdditionsMember2024-01-012024-03-31 0001822791us-gaap:CapitalAdditionsMember2023-01-012023-12-31 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToVisionarymsPhase2ClinicalTrialMember2019-09-012019-09-30 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToRepairmsPhase2ClinicalTrialMember2023-05-012023-05-31 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToRepairmsPhase2ClinicalTrialMember2019-09-012019-09-30 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToVisionarymsPhase2ClinicalTrialMembersrt:MinimumMember2019-09-012019-09-30 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToVisionarymsPhase2ClinicalTrialMembersrt:MaximumMember2019-09-012019-09-30 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToRepairmsPhase2ClinicalTrialMembersrt:MinimumMember2023-05-012023-05-31 0001822791clnn:NationalMultipleSclerosisSocietyMemberclnn:GrantFundingRelatedToRepairmsPhase2ClinicalTrialMembersrt:MaximumMember2023-05-012023-05-31 0001822791clnn:The401kPlanMember2024-01-012024-03-31 0001822791clnn:The401kPlanMember2023-01-012023-03-31 0001822791clnn:The2014StockPlanMember2024-03-31 0001822791clnn:The2020StockPlanMember2023-05-31 0001822791clnn:The2020StockPlanMember2024-01-012024-03-31 0001822791clnn:The2020StockPlanMember2024-03-31 0001822791us-gaap:EmployeeStockOptionMember2024-01-012024-03-31 0001822791us-gaap:EmployeeStockOptionMember2023-01-012023-03-31 0001822791clnn:RestrictedStockAwardsMember2024-01-012024-03-31 0001822791clnn:RestrictedStockAwardsMember2023-01-012023-03-31 00018227912023-10-012023-12-31 0001822791us-gaap:EmployeeStockOptionMember2024-03-31 0001822791us-gaap:EmployeeStockOptionMember2023-12-31 0001822791us-gaap:EmployeeStockOptionMember2023-01-012023-12-31 0001822791srt:MinimumMember2023-01-012023-03-31 0001822791srt:MaximumMember2023-01-012023-03-31 0001822791us-gaap:RestrictedStockMember2023-12-31 0001822791us-gaap:RestrictedStockMember2024-03-31 0001822791us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-31 0001822791us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-31 0001822791us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-31 0001822791us-gaap:USTreasurySecuritiesMember2024-03-31 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-03-31 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-03-31 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2024-03-31 0001822791us-gaap:MoneyMarketFundsMember2024-03-31 0001822791us-gaap:FairValueInputsLevel1Memberclnn:UsTreasurySecuritiesWithMaturityGreaterThan90DaysButLessThan1YearMember2024-03-31 0001822791us-gaap:FairValueInputsLevel2Memberclnn:UsTreasurySecuritiesWithMaturityGreaterThan90DaysButLessThan1YearMember2024-03-31 0001822791us-gaap:FairValueInputsLevel3Memberclnn:UsTreasurySecuritiesWithMaturityGreaterThan90DaysButLessThan1YearMember2024-03-31 0001822791clnn:CommonStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel1Member2024-03-31 0001822791clnn:CommonStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel2Member2024-03-31 0001822791clnn:CommonStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2024-03-31 0001822791clnn:CommonStockWarrantLiabilityMember2024-03-31 0001822791us-gaap:FairValueInputsLevel1Member2024-03-31 0001822791us-gaap:FairValueInputsLevel2Member2024-03-31 0001822791us-gaap:FairValueInputsLevel3Member2024-03-31 0001822791us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-31 0001822791us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-31 0001822791us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-31 0001822791us-gaap:USTreasurySecuritiesMember2023-12-31 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-31 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-31 0001822791us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-12-31 0001822791us-gaap:MoneyMarketFundsMember2023-12-31 0001822791us-gaap:FairValueInputsLevel1Memberclnn:UsTreasurySecuritiesWithMaturityGreaterThan90DaysButLessThan1YearMember2023-12-31 0001822791us-gaap:FairValueInputsLevel2Memberclnn:UsTreasurySecuritiesWithMaturityGreaterThan90DaysButLessThan1YearMember2023-12-31 0001822791us-gaap:FairValueInputsLevel3Memberclnn:UsTreasurySecuritiesWithMaturityGreaterThan90DaysButLessThan1YearMember2023-12-31 0001822791clnn:CommonStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel1Member2023-12-31 0001822791clnn:CommonStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel2Member2023-12-31 0001822791clnn:CommonStockWarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2023-12-31 0001822791clnn:CommonStockWarrantLiabilityMember2023-12-31 0001822791us-gaap:FairValueInputsLevel1Member2023-12-31 0001822791us-gaap:FairValueInputsLevel2Member2023-12-31 0001822791us-gaap:FairValueInputsLevel3Member2023-12-31 0001822791clnn:CleneNanomedicineContingentEarnoutMember2023-12-31 0001822791clnn:InitialStockholdersContingentEarnoutMember2023-12-31 0001822791clnn:CommonStockWarrantLiabilityMember2024-01-012024-03-31 0001822791clnn:CleneNanomedicineContingentEarnoutMember2024-01-012024-03-31 0001822791clnn:InitialStockholdersContingentEarnoutMember2024-01-012024-03-31 0001822791clnn:CleneNanomedicineContingentEarnoutMember2024-03-31 0001822791clnn:InitialStockholdersContingentEarnoutMember2024-03-31 0001822791clnn:CleneNanomedicineContingentEarnoutMember2022-12-31 0001822791clnn:InitialStockholdersContingentEarnoutMember2022-12-31 0001822791clnn:CleneNanomedicineContingentEarnoutMember2023-01-012023-03-31 0001822791clnn:InitialStockholdersContingentEarnoutMember2023-01-012023-03-31 0001822791clnn:CleneNanomedicineContingentEarnoutMember2023-03-31 0001822791clnn:InitialStockholdersContingentEarnoutMember2023-03-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2023-12-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2023-12-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2023-12-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2023-12-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-12-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2023-12-31 0001822791clnn:NewAvenueWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2023-12-31 0001822791clnn:NewAvenueWarrantMemberclnn:MeasurementInputProbabilityOfChangeOfControlMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberclnn:MeasurementInputProbabilityOfChangeOfControlMember2023-12-31 0001822791clnn:NewAvenueWarrantMemberclnn:MeasurementInputProbabilityOfDissolutionMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberclnn:MeasurementInputProbabilityOfDissolutionMember2023-12-31 0001822791clnn:NewAvenueWarrantMemberclnn:MeasurementInputProbabilityOfOtherOutcomeMember2024-03-31 0001822791clnn:NewAvenueWarrantMemberclnn:MeasurementInputProbabilityOfOtherOutcomeMember2023-12-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2024-03-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2024-03-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2023-12-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2023-12-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2024-03-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2024-03-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2023-12-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2023-12-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2024-03-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-12-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2024-03-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2024-03-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2023-12-31 0001822791clnn:TrancheAWarrantMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2023-12-31 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfNdaAcceptanceMember2024-03-31 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfNdaAcceptanceMember2023-12-31 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfFundamentalTransactionMember2024-03-31 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfFundamentalTransactionMember2023-12-31 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfDissolutionMember2024-03-31 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfDissolutionMember2023-12-31 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfOtherOutcomeMember2024-03-31 0001822791clnn:TrancheAWarrantMemberclnn:MeasurementInputProbabilityOfOtherOutcomeMember2023-12-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputPriceVolatilityMember2024-03-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputPriceVolatilityMember2023-12-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-03-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputExpectedDividendRateMembersrt:MinimumMember2024-03-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-12-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputExpectedTermMember2024-03-31 0001822791clnn:ContingentEarnoutSharesMemberus-gaap:MeasurementInputExpectedTermMember2023-12-31 0001822791clnn:CommonStockWarrantExercisableOnDecember2020OneMember2024-03-31 0001822791clnn:CommonStockWarrantExercisableOnDecember2020OneMember2023-12-31 0001822791clnn:CommonStockWarrantExercisableOnDecember2020TwoMember2024-03-31 0001822791clnn:CommonStockWarrantExercisableOnDecember2020TwoMember2023-12-31 0001822791clnn:CommonStockWarrantExercisableOnJune2023OneMember2024-03-31 0001822791clnn:CommonStockWarrantExercisableOnJune2023OneMember2023-12-31 0001822791clnn:CommonStockWarrantExercisableOnJune2023TwoMember2024-03-31 0001822791clnn:CommonStockWarrantExercisableOnJune2023TwoMember2023-12-31 0001822791clnn:CommonStockWarrantExercisableOnJune2023ThreeMember2024-03-31 0001822791clnn:CommonStockWarrantExercisableOnJune2023ThreeMember2023-12-31 0001822791clnn:WarrantsOriginallyIssuedByTottenhamAcquisitionILimitedMember2020-12-30 0001822791clnn:WarrantsOriginallyIssuedByTottenhamAcquisitionILimitedMember2020-12-302020-12-30 0001822791clnn:WarrantsOriginallyIssuedByTottenhamAcquisitionILimitedMember2024-01-012024-03-31 0001822791clnn:WarrantsOriginallyIssuedByTottenhamAcquisitionILimitedMember2023-01-012023-12-31 0001822791clnn:ChardanUnitPurchaseOptionMember2020-12-30 0001822791clnn:ChardanUnitPurchaseOptionMember2024-01-012024-03-31 0001822791clnn:ChardanUnitPurchaseOptionMember2023-01-012023-12-31 0001822791clnn:NewAvenueWarrantMember2023-12-31 0001822791clnn:NewAvenueWarrantMember2024-01-012024-03-31 0001822791clnn:NewAvenueWarrantMember2023-01-012023-12-31 0001822791clnn:TrancheAWarrantMember2023-06-30 0001822791clnn:TrancheAWarrantMember2024-01-012024-03-31 0001822791clnn:TrancheAWarrantMember2023-01-012023-12-31 0001822791clnn:TrancheBWarrantMember2023-06-30 0001822791clnn:TrancheBWarrantMember2024-01-012024-03-31 0001822791clnn:TrancheBWarrantMember2023-01-012023-12-31 0001822791clnn:CanaccordMemberclnn:UnderwritingAgreementMember2023-06-012023-06-30 0001822791clnn:CanaccordMemberclnn:UnderwritingAgreementMember2023-06-30 0001822791clnn:TrancheAWarrantMemberclnn:CanaccordMember2023-06-30 0001822791clnn:TrancheBWarrantMemberclnn:CanaccordMember2023-06-30 0001822791clnn:AtmFacilityMember2022-12-012022-12-31 0001822791us-gaap:SubsequentEventMemberclnn:AtmFacilityMember2024-05-082024-05-08 0001822791clnn:AtmFacilityMember2024-01-012024-03-31 0001822791clnn:AtmFacilityMember2023-10-012023-12-31 0001822791clnn:AtmFacilityMember2023-01-012023-03-31 0001822791clnn:LincolnParkCapitalFundLlcMembersrt:MaximumMember2023-03-03 0001822791clnn:LincolnParkCapitalFundLlcMember2023-03-032023-03-03 0001822791clnn:LincolnParkCapitalFundLlcMember2023-03-03 0001822791clnn:LincolnParkCapitalFundLlcMembersrt:MinimumMember2023-03-03 0001822791clnn:LincolnParkCapitalFundLlcMember2024-03-31 0001822791clnn:LincolnParkCapitalFundLlcMember2023-12-31 0001822791clnn:LincolnParkMemberclnn:PurchaseAgreementMember2024-01-012024-03-31 0001822791clnn:LincolnParkMemberclnn:PurchaseAgreementMember2023-01-012023-03-31 0001822791us-gaap:ConvertibleNotesPayableMember2024-01-012024-03-31 0001822791us-gaap:ConvertibleNotesPayableMember2023-01-012023-03-31 0001822791clnn:CommonStockWarrantsMember2024-01-012024-03-31 0001822791clnn:CommonStockWarrantsMember2023-01-012023-03-31 0001822791us-gaap:EmployeeStockOptionMember2024-01-012024-03-31 0001822791us-gaap:EmployeeStockOptionMember2023-01-012023-03-31 0001822791us-gaap:RestrictedStockMember2024-01-012024-03-31 0001822791us-gaap:RestrictedStockMember2023-01-012023-03-31 0001822791clnn:ContingentEarnoutSharesMember2024-01-012024-03-31 0001822791clnn:ContingentEarnoutSharesMember2023-01-012023-03-31 0001822791clnn:SupplyAgreementMemberclnn:FourLifeMember2018-08-012018-08-31 00018227912018-08-012018-08-31 0001822791clnn:LicenseAgreementMemberclnn:FourLifeMember2024-01-012024-03-31 0001822791us-gaap:ProductMemberus-gaap:RelatedPartyMember2024-01-012024-03-31 0001822791us-gaap:ProductMemberus-gaap:RelatedPartyMember2023-01-012023-03-31 0001822791us-gaap:RoyaltyMemberus-gaap:RelatedPartyMember2024-01-012024-03-31 0001822791us-gaap:RoyaltyMemberus-gaap:RelatedPartyMember2023-01-012023-03-31 0001822791us-gaap:RelatedPartyMember2024-01-012024-03-31 0001822791us-gaap:RelatedPartyMember2023-01-012023-03-31 0001822791clnn:NihGrantAwardedToCleneColumbiaUniversityAndSynapticureMemberus-gaap:SubsequentEventMember2024-04-09 0001822791clnn:NihGrantSubawardsMemberus-gaap:SubsequentEventMember2024-04-09 0001822791clnn:NihGrantSubawardOneMemberus-gaap:SubsequentEventMember2024-04-09 0001822791clnn:NihGrantMemberus-gaap:SubsequentEventMember2023-09-252024-05-08
 


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission file number: 01-39834


CLENE INC.

(Exact name of registrant as specified in its charter)


 

Delaware

 

85-2828339

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

6550 South Millrock Drive, Suite G50

Salt Lake City, Utah

 

84121

(Address of principal executive offices)

 

(Zip Code)

 

 (801) 676-9695 

(Registrant’s telephone number, including area code)

 N/A 

(Former name, former address, and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value

 

CLNN

 

The Nasdaq Capital Market

Warrants, to acquire one-half of one share of Common Stock for $11.50 per share

 

CLNNW

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

  

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

The number of shares outstanding of the Registrant’s common stock as of May 6, 2024 was 128,433,721.

 
 

CLENE INC.

Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024

 

PART IFINANCIAL INFORMATION

1

 

Item 1.

Financial Statements (Unaudited)

1

   

Condensed Consolidated Balance Sheets

1
   

Condensed Consolidated Statements of Operations and Comprehensive Loss

2
   

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

3

   

Condensed Consolidated Statements of Cash Flows

4

   

Notes to Condensed Consolidated Financial Statements

5

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

26

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

39

 

Item 4.

Controls and Procedures

39

       

PART IIOTHER INFORMATION

41

 

Item 1.

Legal Proceedings

41

 

Item 1A.

Risk Factors

41

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

42

 

Item 3.

Defaults Upon Senior Securities

42

 

Item 4.

Mine Safety Disclosures

42

 

Item 5.

Other Information

42

 

Item 6.

Exhibits

42

 

 
 

PART IFINANCIAL INFORMATION

 

Item 1. Financial Statements

 

CLENE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

  

March 31,

  

December 31,

 
  

2024

  

2023

 

ASSETS

        

Current assets:

        

Cash and cash equivalents

 $21,732  $28,821 

Marketable securities

  6,178   6,179 

Accounts receivable

  64   143 

Inventory

  37   37 

Prepaid expenses and other current assets

  4,100   3,672 

Total current assets

  32,111   38,852 

Restricted cash

  58   58 

Operating lease right-of-use assets

  4,046   4,168 

Property and equipment, net

  8,854   9,263 

TOTAL ASSETS

 $45,069  $52,341 
         

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current liabilities:

        

Accounts payable

 $1,645  $1,504 

Accrued liabilities

  3,905   3,720 

Operating lease obligations, current portion

  599   576 

Finance lease obligations, current portion

  7   27 

Notes payable, current portion

  14,987   14,627 

Convertible notes payable, current portion

  5,042   4,876 

Total current liabilities

  26,185   25,330 

Operating lease obligations, net of current portion

  4,720   4,903 

Notes payable, net of current portion

  1,820   1,894 

Convertible notes payable, net of current portion

  5,265   5,258 

Common stock warrant liabilities

  2,790   1,481 

Clene Nanomedicine contingent earn-out liability

  22   75 

Initial Stockholders contingent earn-out liability

  3   10 

TOTAL LIABILITIES

  40,805   38,951 

Commitments and contingencies (Note 9)

          

Stockholders’ equity:

        

Common stock, $0.0001 par value: 300,000,000 and 300,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 128,433,721 and 128,422,851 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively

  13   13 

Additional paid-in capital

  257,914   255,901 

Accumulated deficit

  (253,803)  (242,723)

Accumulated other comprehensive income

  140   199 

TOTAL STOCKHOLDERS’ EQUITY

  4,264   13,390 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 $45,069  $52,341 

 

See accompanying notes to the condensed consolidated financial statements.

 

 

CLENE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

 

   

Three Months Ended March 31,

 
   

2024

   

2023

 

Revenue:

               

Product revenue

  $ 44     $ 64  

Royalty revenue

    29       43  

Total revenue

    73       107  

Operating expenses:

               

Cost of revenue

    16       5  

Research and development

    5,869       7,395  

General and administrative

    3,420       3,439  

Total operating expenses

    9,305       10,839  

Loss from operations

    (9,232 )     (10,732 )

Other income (expense), net:

               

Interest income

    359       172  

Interest expense

    (1,244 )     (1,066 )

Commitment share expense

          (399 )

Change in fair value of common stock warrant liabilities

    (1,309 )      

Change in fair value of Clene Nanomedicine contingent earn-out liability

    53       (55 )

Change in fair value of Initial Stockholders contingent earn-out liability

    7       (7 )

Research and development tax credits and unrestricted grants

    286       314  

Other income, net

          3  

Total other income (expense), net

    (1,848 )     (1,038 )

Net loss before income taxes

    (11,080 )     (11,770 )

Income tax benefit

           

Net loss

    (11,080 )     (11,770 )
                 

Other comprehensive income (loss):

               

Unrealized gain (loss) on available-for-sale securities

    (4 )     14  

Foreign currency translation adjustments

    (55 )     4  

Total other comprehensive income (loss)

    (59 )     18  

Comprehensive loss

  $ (11,139 )   $ (11,752 )
                 

Net loss per share – basic and diluted

  $ (0.09 )   $ (0.15 )

Weighted average common shares used to compute basic and diluted net loss per share

    128,427,231       76,049,665  

 

See accompanying notes to the condensed consolidated financial statements.

 

 

CLENE INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands, except share amounts)

(Unaudited)

 

   

Common Stock

   

Additional Paid-In

   

Accumulated

   

Accumulated Other Comprehensive

   

Total Stockholders’

 
   

Shares

   

Amount

   

Capital

   

Deficit

   

Income (Loss)

   

Equity

 

Balances at December 31, 2023

    128,422,851     $ 13     $ 255,901     $ (242,723 )   $ 199     $ 13,390  

Stock-based compensation expense

                2,013                   2,013  

Issuance of common stock upon vesting of restricted stock awards

    10,870                                

Unrealized loss on available-for-sale securities

                            (4 )     (4 )

Foreign currency translation adjustment

                            (55 )     (55 )

Net loss

                      (11,080 )           (11,080 )

Balances at March 31, 2024

    128,433,721     $ 13     $ 257,914     $ (253,803 )   $ 140     $ 4,264  
                                                 

Balances at December 31, 2022

    74,759,591       7       196,246       (193,219 )     203       3,237  

Issuance of common stock

    3,227,758       1       4,664                   4,665  

Stock-based compensation expense

                2,223                   2,223  

Unrealized gain on available-for-sale securities

                            14       14  

Foreign currency translation adjustment

                            4       4  

Net loss

                      (11,770 )           (11,770 )

Balances at March 31, 2023

    77,987,349     $ 8     $ 203,133     $ (204,989 )   $ 221     $ (1,627 )

 

See accompanying notes to the condensed consolidated financial statements.

 

 

CLENE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

   

Three Months Ended March 31,

 
   

2024

   

2023

 

Cash flows from operating activities:

               

Net loss

  $ (11,080 )   $ (11,770 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Depreciation

    420       402  

Non-cash lease expense

    122       108  

Commitment share expense

          399  

Change in fair value of common stock warrant liabilities

    1,309        

Change in fair value of Clene Nanomedicine contingent earn-out liability

    (53 )     55  

Change in fair value of Initial Stockholders contingent earn-out liability

    (7 )     7  

Stock-based compensation expense

    2,013       2,223  

Accretion of debt discount

    367       250  

Non-cash interest income on marketable securities

    (81 )      

Non-cash interest expense on notes payable

    91       82  

Changes in operating assets and liabilities:

               

Accounts receivable

    79       126  

Inventory

          (45 )

Prepaid expenses and other current assets

    (428 )     (581 )

Accounts payable

    141       (2,406 )

Accrued liabilities

    185       2,070  

Operating lease obligations

    (160 )     (138 )

Net cash used in operating activities

    (7,082 )     (9,218 )

Cash flows from investing activities:

               

Purchases of marketable securities

    (6,168 )      

Proceeds from maturities of marketable securities

    6,250       5,000  

Purchases of property and equipment

    (11 )     (278 )

Net cash provided by investing activities

    71       4,722  

Cash flows from financing activities:

               

Proceeds from issuance of common stock and warrants, net of offering costs

          4,266  

Payments of finance lease obligations

    (19 )     (28 )

Proceeds from the issuance of notes payable

          350  

Net cash provided by (used in) financing activities

    (19 )     4,588  

Effect of foreign exchange rate changes on cash and restricted cash

    (59 )     18  

Net increase (decrease) in cash, cash equivalents and restricted cash

    (7,089 )     110  

Cash, cash equivalents and restricted cash – beginning of period

    28,879       18,390  

Cash, cash equivalents and restricted cash – end of period

  $ 21,790     $ 18,500  
                 

Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets

               

Cash and cash equivalents

  $ 21,732     $ 18,442  

Restricted cash

    58       58  

Cash, cash equivalents and restricted cash

  $ 21,790     $ 18,500  
                 

Supplemental cash flow information:

               

Cash paid for interest expense

  $ 784     $ 982  

 

See accompanying notes to the condensed consolidated financial statements.

 

 

CLENE INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1. Nature of the Business

 

Clene Inc. (the “Company,” “we,” “us,” or similar such references) is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. We have developed an electro-crystal-chemistry drug development platform which enables production of concentrated, stable, highly active, clean-surfaced nanocrystal suspensions. We have multiple drug assets currently in development for applications primarily in neurology. Our efforts are currently focused on addressing the high unmet medical needs in central nervous system disorders including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”). Our patented electro-crystal-chemistry manufacturing platform further enables us to develop very low concentration dietary supplements to advance the health and well-being of broad populations. These dietary supplements can vary greatly and include nanocrystals of varying composition, shapes and sizes as well as ionic solutions with diverse metallic constituents. Dietary supplements are marketed and distributed through our wholly owned subsidiary, dOrbital, Inc., or through an exclusive license with 4Life Research LLC (“4Life”), an international supplier of health supplements, stockholder, and related party (see Note 15).

 

Clene Nanomedicine, Inc. (“Clene Nanomedicine”) became a public company on December 30, 2020 (the “Closing Date”) when it completed a reverse recapitalization (the “Reverse Recapitalization”) with Tottenham Acquisition I Limited (“Tottenham”), Tottenham’s wholly-owned subsidiary and our predecessor, Chelsea Worldwide Inc., and Creative Worldwide Inc., a wholly-owned subsidiary of Chelsea Worldwide Inc. On the Closing Date, Chelsea Worldwide Inc. changed its name to Clene Inc. and listed its shares of common stock, par value $0.0001 per share (“Common Stock”) on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CLNN.”

 

Going Concern

 

We incurred a loss from operations of $9.2 million and $10.7 million for the three months ended March 31, 2024 and 2023, respectively. Our accumulated deficit was $253.8 million and $242.7 million as of March 31, 2024 and December 31, 2023, respectively. Our cash, cash equivalents, and marketable securities totaled $27.9 million and $35.0 million as of March 31, 2024 and December 31, 2023, respectively, and net cash used in operating activities was $7.1 million and $9.2 million for the three months ended March 31, 2024 and 2023, respectively.

 

We have incurred significant losses and negative cash flows from operations since our inception. We have not generated significant revenues since our inception, and we do not anticipate generating significant revenues unless we successfully complete development and obtain regulatory approval for commercialization of a drug candidate. We expect to incur additional losses in the future, particularly as we advance the development of our clinical-stage drug candidates, continue research and development of our preclinical drug candidates, and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug candidates. We expect that within the next twelve months, we will not have sufficient cash and other resources on hand to sustain our current operations or meet our obligations as they become due unless we obtain additional financing. Additionally, pursuant to our term loan with Avenue Venture Opportunities Fund, L.P. (“Avenue”), we are required to maintain unrestricted cash and cash equivalents of at least $5.0 million to avoid acceleration of the full balance of the loan (see Note 8). These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

 

To mitigate our funding needs, we plan to raise additional funding, including exploring equity financing and offerings, debt financing, licensing or collaboration arrangements with third parties, as well as utilizing our existing at-the-market facility, equity purchase agreement, and potential proceeds from the exercise of outstanding warrants and stock options. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of our plans will result in the necessary funding to continue current operations. We have implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts and elimination of certain staff positions. We have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued.

 

The accompanying condensed consolidated financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As a result, the accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

 

5

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements include the accounts of Clene Inc. and our wholly-owned subsidiaries, Clene Nanomedicine, Inc., a subsidiary incorporated in Delaware, Clene Australia Pty Ltd (“Clene Australia”), a subsidiary incorporated in Australia, Clene Netherlands B.V. (“Clene Netherlands”), a subsidiary incorporated in the Netherlands, and dOrbital, Inc., a subsidiary incorporated in Delaware, after elimination of all intercompany accounts and transactions. We have prepared the accompanying condensed consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. The condensed consolidated financial statements have been prepared on the same basis as our audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The financial data and other information disclosed in the condensed consolidated financial statements and related notes for the three months ended March 31, 2024 and 2023 are unaudited.

 

Results of operations for the three months ended March 31, 2024 and 2023 are not necessarily indicative of the results for the entire fiscal year or any other period. The condensed consolidated financial statements for the three months ended March 31, 2024 and 2023 should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.

 

Risks and Uncertainties

 

We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial condition, results of operations, or cash flows: ability to obtain additional financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of third-party contract research organizations (“CROs”) and manufacturers upon which we rely; protection of our intellectual property; litigation or claims against us based on intellectual property, patent, product, regulatory, or other factors; and our ability to attract and retain employees necessary to support our growth. The product candidates we develop require approvals from regulatory agencies prior to commercial sales. There can be no assurance that our current and future product candidates will receive the necessary approvals or be commercially successful. If we are denied approval or approval is delayed, it will have a material adverse impact on our business and our condensed consolidated financial statements.

 

Concentrations of Credit Risk

 

Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is held in financial institutions and amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

 

Cash and Cash Equivalents

 

We consider all short-term investments with original maturities of 90 days or less when purchased to be cash equivalents.

 

Restricted Cash

 

We classify cash as restricted when it is unavailable for withdrawal or use in our general operating activities. Restricted cash is classified as current and noncurrent on the condensed consolidated balance sheets based on the nature of the restriction. Our restricted cash balance includes contractually restricted deposits related to our corporate credit card.

 

6

 

Marketable Securities

 

Marketable securities are investments with original maturities of more than 90 days when purchased. We do not invest in securities with original maturities of more than one year. Marketable debt securities are considered available-for-sale, and are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income until realized. Realized gains and losses are included in other income (expense), net, on the basis of specific identification. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in other income (expense), net.

 

Inventory

 

Inventory is stated at historic cost on a first-in first-out basis. Our inventory consisted of $23,000 in raw materials and $14,000 in finished goods as of March 31, 2024, and $23,000 in raw material and $14,000 in finished goods as of December 31, 2023. Inventory relates to our dietary supplement products.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Property and equipment consist of laboratory and office equipment, computer software, and leasehold improvements. Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3 to 5 years for laboratory equipment, 3 to 7 years for furniture and fixtures, and 2 to 5 years for computer software. Leasehold improvements are amortized over the lesser of the estimated lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in the condensed consolidated statements of operations and comprehensive loss. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.

 

We capitalize costs to obtain or develop computer software for internal use, including development costs incurred during the software development stage and costs to obtain software for access and conversion of historical data. We also capitalize costs to modify, upgrade, or enhance existing internal-use software that result in additional functionality. We expense costs incurred during the preliminary project stage, training costs, data conversion costs, and maintenance costs.

 

Debt

 

When debt is issued and a derivative is required to be separated (e.g., bifurcated conversion option) or another separate freestanding financial instrument (e.g., warrant) is issued, costs and fees incurred are allocated to the instruments issued (or bifurcated) in proportion to the allocation of proceeds. When some portions of the costs and fees relate to a bifurcated derivative or freestanding financial instrument that is being subsequently measured at fair value, those allocated costs are expensed immediately. Debt discounts, debt premiums, and debt issuance costs related to debt are recorded as deductions that net against the principal value of the debt and are amortized to interest expense over the contractual term of the debt using the effective interest method.

 

In accordance with ASC 470-20, Debt with Conversion and Other Options, when we issue debt with warrants, we treat the warrants as a debt discount, recorded as a contra-liability against the debt, and amortize the balance over the life of the underlying debt as interest expense in the condensed consolidated statements of operations and comprehensive loss. The offset to the contra-liability is recorded as additional paid-in capital in the condensed consolidated balance sheets if the warrants are not treated as a derivative or liability under ASC 480, Distinguishing Liabilities from Equity (“ASC 480”). Otherwise, the offset to the contra-liability is recorded as a warrant liability in the condensed consolidated balance sheets and is subject to re-measurement to fair value at each balance sheet date, with any changes in fair value recognized in the condensed consolidated statements of operations and comprehensive loss. If the debt is retired early, the associated debt discount is then recognized immediately as interest expense in the condensed consolidated statements of operations and comprehensive loss.

 

7

 

Convertible Debt

 

In accordance with ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, when we issue notes with conversion features, we evaluate if the conversion feature is freestanding or embedded. If the conversion feature is embedded, we do not separate the conversion feature from the host contract for convertible notes that are not required to be accounted for as derivatives, or that do not result in substantial premiums accounted for as paid-in-capital. Consequently, we account for a convertible note as a single liability measured at its amortized cost as long as no other features require separation and recognition as derivatives. If the conversion feature is freestanding, or is embedded and meets the requirements to be separated, we account for the conversion feature as a derivative under ASC 815, Derivatives and Hedging (“ASC 815”). We record the derivative instrument at fair value at inception, and subsequently re-measure to fair value at each reporting period and immediately prior to the extinguishment of the derivative instrument, with any changes recorded in the condensed consolidated statements of operations and comprehensive loss.

 

Leases

 

At inception of a contract, we determine if a contract meets the definition of a lease. We determine if the contract conveys the right to control the use of an identified asset for a period of time. We assess throughout the period of use whether we have both of the following: (i) the right to obtain substantially all the economic benefits from use of the identified asset, and (ii) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments less any lease incentives received. At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, our incremental borrowing rate is used as the discount rate. Our policy is to not record leases with an original term of twelve months or less within the condensed consolidated balance sheets and we recognize lease expense for these short-term leases on a straight-line basis over the lease term.

 

Certain lease agreements may require us to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as non-lease components. Such variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments is incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.

 

Leases may contain clauses for renewal at our option. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised, or is not at our option. We determine whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. Operating lease expense, which is recognized on a straight-line basis over the lease term, and the amortization of finance lease right-of-use assets, which are included in property and equipment and depreciated, are included in research and development or general and administrative expenses consistent with the leased assets’ primary use. Accretion on the liabilities for finance leases is included in interest expense.

 

Contingent Earn-Out Liabilities

 

In connection with the Reverse Recapitalization, certain Clene Nanomedicine stockholders are entitled to receive additional shares of Common Stock (the “Clene Nanomedicine Contingent Earn-out”) as follows: (i) 3,338,483 shares if (a) the volume-weighted average price (“VWAP”) of our Common Stock equals or exceeds $15.00 (the “Milestone 1 Price”) in any twenty trading days within a thirty trading day period within three years of the Reverse Recapitalization or (b) the change of control price equals or exceeds the Milestone 1 Price if a change of control transaction occurs within three years of the closing of the Reverse Recapitalization (the requirements in (a) and (b) collectively, “Milestone 1”); (ii) 2,503,851 shares if (a) the VWAP of our Common Stock equals or exceeds $20.00 (the “Milestone 2 Price”) in any twenty trading days within a thirty trading day period within five years of the closing of the Reverse Recapitalization or (b) the change of control price equals or exceeds the Milestone 2 Price if a change of control transaction occurs within five years of the Reverse Recapitalization (the requirements in (a) and (b) collectively, “Milestone 2”). If Milestone 1 is not achieved but Milestone 2 is achieved, the Clene Nanomedicine stockholders will receive additional shares equal to Milestone 1. Tottenham’s former officers, directors, sponsor, and public stockholders (the “Initial Stockholders”) are entitled to receive earn-out shares (the “Initial Stockholders Contingent Earn-out,” and collectively with the Clene Nanomedicine Contingent Earn-out, the “Contingent Earn-outs”) as follows: (i) 375,000 shares upon the achievement of Milestone 1; and (ii) 375,000 shares upon achievement of Milestone 2. If Milestone 1 is not achieved but Milestone 2 is achieved, the Initial Stockholders will receive additional shares equal to Milestone 1.

 

In accordance with ASC 815, the Contingent Earn-outs are not indexed to our own stock and therefore were accounted for as a liability at the Reverse Recapitalization date and are subsequently remeasured to fair value at each reporting date with changes recorded as a component of other income (expense), net.

 

8

 

Common Stock Warrants

 

We account for common stock warrants as either equity- or liability-classified instruments based on an assessment of the warrant terms. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all the requirements for equity classification under ASC 815, including whether the warrants are indexed to our Common Stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for liability-classified warrants, at each reporting period end date while the warrants are outstanding.

 

Grant Funding

 

We may submit applications to receive grant funding from governmental and non-governmental entities. We account for grants by analogizing to the grant accounting model under IAS 20, Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). We recognize grant funding without conditions or continuing performance obligations, including certain research and development tax credits, as other income in the condensed consolidated statements of operations and comprehensive loss. We accrue certain research and development tax credits receivable in other current assets (see Note 4) in an amount equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage and we recognize other income in the condensed consolidated statements of operations and comprehensive loss. After submission of our tax returns, we receive a cash refund of certain research and development tax credits and relieve the receivable.

 

We recognize grant funding with conditions or continuing performance obligations as a reduction in research and development expenses in the period during which the related qualifying expenses are incurred and as the conditions or performance obligations are fulfilled. Any amount received in advance of fulfilling such conditions or performance obligations is recorded in accrued liabilities (see Note 6) if the conditions or performance obligations are expected to be met within the next twelve months. We recognized grant funding of $0.3 million and $0 as a reduction of research and development expenses during the three months ended March 31, 2024 and 2023, respectively.

 

Foreign Currency Translation and Transactions

 

Our functional and reporting currency is the U.S. dollar (“USD”). Clene Australia and Clene Netherlands determined their functional currencies to be the Australian dollar and Euro, respectively. The results of our foreign currency operations are translated into USD at the average exchange rates during the period, assets and liabilities are translated using the exchange rate as of the balance sheet date, and stockholders’ equity is translated using historical rates. Adjustments from the translation of the results of our foreign currency operations are excluded from net loss and are accumulated in a separate component of stockholders’ equity. We also incur foreign exchange transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange transaction gains and losses are included in other income (expense), net, as incurred.

 

Comprehensive Loss

 

Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. The only elements of other comprehensive loss in any periods presented were the translation of foreign currency denominated balances of Clene Australia and Clene Netherlands to USD for consolidation and our unrealized gain (loss) on available-for-sale securities.

 

Segment Information

 

We report segment information based on ASC 280 Segment Reporting (“ASC 280”), which defines operating segments as components of a company that engage in activities from which it may recognize revenues and incur expenses, and for which operating results are regularly reviewed by the entity’s chief operating decision maker (“CODM”) to make decisions regarding resource allocation and assess performance, and for which discrete financial information is available. Effective in the fourth quarter of 2023, we revised our internal reporting processes to better align with our strategic priorities due to the immateriality of our dietary supplement operations. As a result and in accordance with ASC 280, we determined that the Company is a single operating and reportable segment. Our chief executive officer is the CODM and allocates resources and assesses performance at a consolidated level. Prior to the fourth quarter of 2023, we operated as two operating and reportable segments related to our development and commercialization of drugs and dietary supplements. The change did not require any prior period information to be recast.

 

9

 

Income Taxes

 

We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in our tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. We assess the likelihood that our deferred tax assets will be recovered from future taxable income and, to the extent we believe, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

 

We account for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, which are considered appropriate as well as the related net interest and penalties.

 

Stock-Based Compensation

 

We account for stock-based compensation arrangements using a fair value-based method for costs related to all share-based payments including stock options and stock awards. Stock-based compensation expense is recorded in research and development and general and administrative expenses based on the classification of the work performed by the grantees. The fair value is recognized over the period during which a grantee is required to provide services in exchange for the option award and service-based stock awards, known as the requisite service period (usually the vesting period), on a straight-line basis. For stock awards with market conditions, the fair value is recognized over the period based on the expected milestone achievement dates as the derived service period (usually the vesting period), on a straight-line basis. For stock awards with performance conditions, the grant-date fair value of these awards is the market price on the applicable grant date, and compensation expense will be recognized when the conditions become probable of being satisfied. We recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related service period had been completed in a prior period. We elect to account for forfeitures as they occur, rather than estimating expected forfeitures. We determine the fair value of each share of Common Stock underlying stock-based awards using a Black-Scholes option pricing model based on the closing price of our Common Stock as reported by Nasdaq on the date of grant. The fair value of stock awards with market conditions are determined using a Monte Carlo valuation model.

 

Recent Accounting Pronouncements Not Yet Adopted

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 requires, among other things, that public entities with a single reportable segment provide all the disclosures required by ASC 280 and ASU 2023-07, and that public entities provide all annual disclosures about a reportable segment’s profit or loss and assets currently required in interim periods. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact of ASU 2023-07.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires, among other things, that public entities on an annual basis disclose specific categories of the tax rate reconciliation, provide additional information for reconciling items that meet a quantitative threshold, and disclose income taxes paid disaggregated by jurisdiction. The guidance is effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact of ASU 2023-09.

 

10

 

Note 3. Cash, Cash Equivalents, and Marketable Securities

 

Available-for-Sale Securities

 

Available-for-sale securities as of March 31, 2024 were as follows:

 

  

March 31, 2024

 

(in thousands)

 

Amortized Cost

  

Gross Unrealized Gains

  

Gross Unrealized Losses

  

Fair Value

 

Cash equivalents (contractual maturity within 90 days):

                

U.S. Treasury securities

 $12,192  $  $(1) $12,191 

Money market funds

  5,660         5,660 

Total cash equivalents

  17,852      (1)  17,851 

Cash

  3,881         3,881 

Total cash and cash equivalents

 $21,733  $  $(1) $21,732 
                 

Marketable securities (contractual maturity greater than 90 days but less than 1 year):

                

U.S. Treasury securities

 $6,179  $  $(1) $6,178 

Total marketable securities

 $6,179  $  $(1) $6,178 

 

Available-for-sale securities as of  December 31, 2023 were as follows:

 

  

December 31, 2023

 

(in thousands)

 

Amortized Cost

  

Gross Unrealized Gains

  

Gross Unrealized Losses

  

Fair Value

 

Cash equivalents (contractual maturity within 90 days):

                

U.S. Treasury securities

 $19,883  $1  $  $19,884 

Money market funds

  5,113         5,113 

Total cash equivalents

  24,996   1      24,997 

Cash

  3,824         3,824 

Total cash and cash equivalents

 $28,820  $1  $  $28,821 
                 

Marketable securities (contractual maturity greater than 90 days but less than 1 year):

                

U.S. Treasury securities

 $6,179  $  $  $6,179 

Total marketable securities

 $6,179  $  $  $6,179 

 

We received proceeds of $6.3 million and $5.0 million from the maturity of marketable securities during the three months ended March 31, 2024 and 2023, respectively. We had no realized gains or losses from the sale of available-for-sale securities during the three months ended March 31, 2024 and 2023. As of March 31, 2024 and December 31, 2023, we did not have any allowance for credit losses or impairments of available-for-sale securities.

 

11

 

Note 4. Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets as of March 31, 2024 and December 31, 2023 were as follows:

 

   

March 31,

   

December 31,

 

(in thousands)

 

2024

   

2023

 

Metals to be used in research and development

  $ 1,826     $ 1,909  

Research and development tax credits receivable

    1,442       1,195  

Other

    832       568  

Total prepaid expenses and other current assets

  $ 4,100     $ 3,672  
 

Note 5. Property and Equipment, Net

 

Property and equipment, net, as of March 31, 2024 and December 31, 2023 were as follows:

 

   

March 31,

   

December 31,

 

(in thousands)

 

2024

   

2023

 

Lab equipment

  $ 4,065     $ 4,092  

Office equipment

    177       178  

Computer software

    459       459  

Leasehold improvements

    9,983       9,983  

Construction in progress

    1,449       1,438  
      16,133       16,150  

Less accumulated depreciation

    (7,279 )     (6,887 )

Total property and equipment, net

  $ 8,854     $ 9,263  

 

Depreciation expense recorded in research and development expense and general and administrative expense for the three months ended March 31, 2024 and 2023 was as follows:

 

   

Three Months Ended March 31,

 

(in thousands)

 

2024

   

2023

 

General and administrative

  $ 66     $ 67  

Research and development

    354       335  

Total depreciation expense

  $ 420     $ 402  
 

Note 6. Accrued Liabilities

 

Accrued liabilities as of March 31, 2024 and December 31, 2023 were as follows:

 

   

March 31,

   

December 31,

 

(in thousands)

 

2024

   

2023

 

Accrued compensation and benefits

  $ 2,628     $ 2,120  

Accrued CRO and clinical fees

    746       481  

Other

    531       1,119  

Total accrued liabilities

  $ 3,905     $ 3,720  
 

Note 7. Leases

 

We lease laboratory and office space and certain laboratory equipment under non-cancellable operating and finance leases. The carrying value of our right-of-use lease assets is substantially concentrated in our real estate leases, while the volume of lease agreements is primarily concentrated in equipment leases. We expect that, in the normal course of business, the existing leases will be renewed or replaced by similar leases.

 

12

 

Operating Leases

 

Operating leases primarily consist of real estate leases for office and laboratory space. We have three real estate leases: (i) a laboratory and manufacturing facility which commenced in September 2021 with a ten-year term and an option to extend for two five-year periods, (ii) a laboratory and manufacturing facility which commenced in February 2022 with a seven-year term and an option to extend for two five-year periods, and (iii) our corporate office which commenced a renewed term in September 2022 for seven years with an option to extend for five years. We did not recognize the payments to be made in the option periods as part of the right-of-use asset or lease liability because the exercise of the option is not reasonably certain.

 

As of March 31, 2024 and December 31, 2023, our operating lease obligations had a weighted-average discount rate of 9.6% and 9.6%, respectively, and a weighted-average remaining term of 6.1 years and 6.4 years, respectively.

 

Finance Leases

 

Assets recorded under finance lease obligations and included within property and equipment as of March 31, 2024 and December 31, 2023 were as follows:

 

   

March 31,

   

December 31,

 

(in thousands)

 

2024

   

2023

 

Lab equipment

  $ 636     $ 636  

Less accumulated depreciation

    (469 )     (449 )

Net

  $ 167     $ 187  

 

As of March 31, 2024 and December 31, 2023, our finance lease obligations had a weighted-average interest rate of 11.0% and 11.0%, respectively, and a weighted-average remaining term of 0.1 years and 0.4 years, respectively.

 

Maturity Analysis of Lease Obligations

 

The maturity analysis of our finance and operating lease obligations as of March 31, 2024 was as follows:

 

(in thousands)

 

Finance Leases

   

Operating Leases

 

2024 (remainder)

  $ 7     $ 789  

2025

          1,208  

2026

          1,236  

2027

          1,132  

2028

          1,093  

2029

          649  

Thereafter

          1,045  

Total minimum lease payments

    7       7,152  

Less amount representing interest/discounting

          (1,833 )

Present value of minimum lease payments

    7       5,319  

Less lease obligations, current portion

    (7 )     (599 )

Lease obligations, net of current portion

  $     $ 4,720  

 

13

 

Components of Lease Cost

 

The components of finance and operating lease costs for the three months ended March 31, 2024 and 2023 were as follows:

 

   

Three Months Ended March 31,

 

(in thousands)

 

2024

   

2023

 

Finance lease costs:

               

Amortization

  $ 27     $ 20  

Interest on lease liabilities

          6  

Operating lease costs

    254       253  

Variable lease costs

    53       50  

Total lease costs

  $ 334     $ 329  

 

Supplemental Cash Flow Information

 

   

Three Months Ended March 31,

 

(in thousands)

 

2024

   

2023

 

Operating cash flows from operating leases

  $ (307 )   $ (303 )

Operating cash flows from finance leases

  $     $ (6 )

Financing cash flows from finance leases

  $ (19 )   $ (28 )
 

Note 8. Notes Payable and Convertible Notes Payable

 

Our notes payable and convertible notes payable as of March 31, 2024 and December 31, 2023 was as follows:

 

   

Stated

   

March 31,

   

December 31,

 

(in thousands, except interest rates)

 

Interest Rate

   

2024

   

2023

 

Notes payable

                       

Advance Cecil, Inc. (commenced April 2019)

    8.00 %   $ 140     $ 138  

Maryland DHCD (commenced February 2019)

    8.00 %     704       694  

Maryland DHCD (commenced May 2022)

    6.00 %     1,083       1,083  

Avenue Venture Opportunities Fund, L.P. (commenced May 2021)

    15.10 %     15,000       15,000  
              16,927       16,915  

Less unamortized discount and debt issuance costs

            (120 )     (394 )

Less notes payable, current portion, net of unamortized discount and debt issuance costs

            (14,987 )     (14,627 )

Total notes payable, net of current portion

          $ 1,820     $ 1,894  
                         

Convertible notes payable

                       

Avenue Venture Opportunities Fund, L.P. (commenced May 2021)

    15.10 %   $ 5,000     $ 5,000  

Maryland DHCD (commenced December 2022)

    6.00 %     5,388       5,308  
              10,388       10,308  

Less unamortized discount and debt issuance costs

            (81 )     (174 )

Less convertible notes payable, current portion, net of unamortized discount and debt issuance costs

            (5,042 )     (4,876 )

Total convertible notes payable, net of current portion

          $ 5,265     $ 5,258  

 

14

 

Maryland Loans

 

In February 2019, we entered into a term loan agreement (the “2019 MD Loan”) with the Department of Housing and Community Development (“DHCD”), a principal department of the State of Maryland, for $0.5 million bearing simple interest at an annual rate of 8.00%. We are subject to covenants until maturity, including limitations on our ability to retire, repurchase, or redeem our stock, options, and warrants other than per the terms of the securities; and limitations on our ability to pay dividends. We are not in violation of any covenants. The 2019 MD Loan established “Phantom Shares” based on 119,907 shares of Common Stock. The 2019 MD Loan matures in full on February 22, 2034, with the repayment amount equal to the greater of (i) principal plus accrued interest or (ii) the Phantom Shares multiplied by the closing price of our Common Stock on Nasdaq on the trading day prior to the maturity date. As of March 31, 2024 and December 31, 2023, the 2019 MD Loan was recorded at principal plus accrued interest as it was greater than the value of the Phantom Shares. We recognized interest expense of $10,000 and $10,000 for the three months ended March 31, 2024 and 2023, respectively.

 

In April 2019, we entered into a term loan agreement (the “2019 Cecil Loan”) with Advance Cecil Inc., a non-stock corporation formed under the laws of the State of Maryland, for $0.1 million bearing simple interest at an annual rate of 8.00%. The 2019 Cecil Loan established “Phantom Shares” based on 23,981 shares of Common Stock. The 2019 Cecil Loan matures in full on April 30, 2034, with the repayment amount equal to the greater of (i) principal plus accrued interest or (ii) the Phantom Shares multiplied by the closing price of our Common Stock on Nasdaq on the trading day prior to the maturity date. As of March 31, 2024 and December 31, 2023, the 2019 Cecil Loan was recorded at principal plus accrued interest as it was greater than the value of the Phantom Shares. We recognized interest expense of $2,000 and $2,000 for the three months ended March 31, 2024 and 2023, respectively.

 

In May 2022, we entered into a term loan agreement (the “2022 MD Loan”) with DHCD for up to $3.0 million bearing simple interest at an annual rate of 6.00% for the purchase of certain manufacturing equipment (the “Assets”). As of March 31, 2024, we had drawn $1.0 million with the remainder available for future equipment purchases until May 17, 2024. The first 12 payments, commencing July 1, 2022, are deferred, followed by 18 monthly installments of interest-only based on the outstanding principal, each up to $15,000 maximum; followed by monthly installments of principal and interest in the amount of $33,306, payable for the lesser of 30 months or until the principal and accrued and unpaid interest is fully repaid, with a balloon payment of all remaining principal and unpaid interest due on the maturity date of July 1, 2027. As of March 31, 2024 and December 31, 2023, the balance of accrued and unpaid interest was $50,000 and $50,000, respectively, and is recorded as part of the carrying amount of the loan. We recorded debt issuance costs of $31,000 as a debt discount. Under an agreement between DHCD and Avenue, an existing secured creditor of the Company, DHCD was granted a first priority lien on the Assets as collateral. We recognized interest expense of $15,000 and $12,000 for the three months ended March 31, 2024 and 2023, respectively.

 

In December 2022, we entered into a term loan agreement (the “2022 DHCD Loan”) with DHCD for $5.0 million bearing simple interest at an annual rate of 6.00%. The first 12 payments, commencing January 1, 2023, are deferred, followed by 48 monthly installments of interest-only, with a balloon payment of all principal and unpaid interest due on the maturity date of January 1, 2028. As of March 31, 2024 and December 31, 2023, the balance of accrued and unpaid interest was $0.4 million and $0.3 million, respectively, and is recorded as part of the carrying amount of the loan. We recorded debt issuance costs of $0.1 million as a debt discount. At any time after December 8, 2023, DHCD may, in its sole discretion, convert up to $5.0 million of principal into Common Stock in increments of $1.0 million, at a price equal to the greater of: (i) 97% of the 30-day trailing VWAP of our Common Stock; or (ii) $4.00 per share (the “DHCD Conversion Feature”). The DHCD Conversion Feature did not meet the requirements for derivative accounting. For the three months ended March 31, 2024 and 2023, we recognized (i) total interest expense of $0.1 million and $0.1 million, respectively; (ii) coupon interest expense of $0.1 million and $0.1 million, respectively; and (iii) amortization of debt issuance costs of $3,000 and $3,000, respectively; and the effective interest rate was 5.99%.

 

Avenue Loan

 

In May 2021, we entered into a term loan agreement (the “2021 Avenue Loan”) with Avenue for up to $30.0 million, bearing interest at a variable rate equal to (i) the greater of (a) the prime rate or (b) 3.25%, plus (ii) 6.60%. As of March 31, 2024 and December 31, 2023, the interest rate was 15.10% and 14.10%, respectively. We borrowed $15.0 million in May 2021 plus $5.0 million in September 2021 (“Tranche 1”), and the remaining $10.0 million (“Tranche 2”) was not drawn and expired. We incurred $0.8 million of debt issuance costs of which $47,000 related to liability-classified warrants was expensed immediately and the remainder was recorded as a debt discount. Payments were interest-only for the first 12 months and the interest-only period was extended for (i) 12 months due to our achievement of certain clinical trial milestones, plus (ii) an additional 12 months (through June 30, 2024), pursuant to an amendment in June 2023 (the “Second Amendment”), due to our receipt of at least $35.0 million from the sale and issuance of Common Stock in a public offering in June 2023 (“Equity Milestone 1”). The interest-only period may be extended through December 31, 2024, subject to (i) our receipt of net proceeds of at least $40.0 million, in addition to Equity Milestone 1, from the sale and issuance of our equity securities on or before June 30, 2024 (“Equity Milestone 2”), and (ii) acceptance of a New Drug Application (“NDA”) by the U.S. Food and Drug Administration (“FDA”) filed by us for the treatment of ALS (the “ALS NDA Milestone”). Following the interest-only period, we are required to make equal monthly installments of principal plus interest at the variable rate then in effect until December 1, 2024, which may be extended to December 1, 2025, so long as no event of default has occurred and is continuing and we have achieved (i) Equity Milestone 2 and (ii) the ALS NDA Milestone. Additionally, a payment of 4.25% of the funded principal, equal to $0.9 million (the “Final Payment”), is due at maturity, which we recorded as a debt premium.

 

15

 

At any time between May 21, 2022 and May 21, 2024, Avenue may, in its sole discretion, convert up to $5.0 million of outstanding principal into Common Stock at $10.36 per share (the “Avenue Conversion Feature”), subject to certain price and volume restrictions related to our Common Stock on Nasdaq. The Final Payment and Avenue Conversion Feature did not meet the requirements for derivative accounting. As of March 31, 2024 and December 31, 2023, unamortized debt discount and issuance costs related to the convertible note were $33,000 and $0.1 million, respectively. For the convertible note for the three months ended March 31, 2024 and 2023, we recognized (i) total interest expense of $0.3 million and $0.2 million, respectively; (ii) coupon interest expense of $0.2 million and $0.2 million, respectively; and (iii) amortization of debt discount and issuance costs of $0.1 million and $0.1 million, respectively; and the effective interest rate was 22.79% and 20.17%, respectively.

 

We are subject to covenants until maturity, including limitations on our ability to retire, repurchase, or redeem our stock, options, and warrants other than per the terms of the securities; limitations on our ability to pay dividends; and we are required to maintain unrestricted cash and cash equivalents of at least $5.0 million. We are not in violation of any covenants. Avenue has the ability to immediately accelerate all obligations under the 2021 Avenue Loan upon the occurrence of certain events of default or material adverse effects. The 2021 Avenue Loan is collateralized by substantially all our assets other than intellectual property, including our capital stock and the capital stock of our subsidiaries, in which Avenue is granted a continuing security interest. We recognized interest expense of $1.1 million and $1.0 million for the three months ended March 31, 2024 and 2023, respectively.

 

At the inception of the 2021 Avenue Loan, we issued a warrant to Avenue to purchase 115,851 shares of Common Stock at $8.63 per share (the “Original Avenue Warrant”). A portion of the net proceeds at issuance of the 2021 Avenue Loan were allocated to the Original Avenue Warrant in an amount equal to its fair value of $1.5 million and were recorded as a debt discount. Pursuant to the Second Amendment, the Original Avenue Warrant was cancelled and a new warrant to purchase 3,000,000 shares of Common Stock at $0.80 per share was issued (the “New Avenue Warrant”). Avenue may exercise the New Avenue Warrant for cash or on a net or “cashless” basis. In the event of a change of control of the Company, the New Avenue Warrant shall be automatically exchanged for the number of shares of Common Stock which remain exercisable thereunder immediately prior to the change of control transaction, for no payment or consideration from Avenue for such shares, and the New Avenue Warrant shall be terminated. At issuance, the New Avenue Warrant was recorded as a liability and debt discount in amount equal to its fair value of $0.7 million. The Second Amendment, including the revised terms, cancellation of the Original Avenue Warrant, and issuance of the New Avenue Warrant was accounted for as a debt modification.

 

Debt Maturities

 

Future debt payments, net of unamortized discounts and debt issuance costs, and without giving effect to any potential future exercise of conversion features, are as follows:

 

(in thousands)

 

2019 MD Loan

   

2019 Cecil Loan

   

2021 Avenue Loan

   

2022 MD Loan

   

2022 DHCD Loan

 

2024 (remainder)

  $     $     $ 20,000     $     $  

2025

                      347        

2026

                      369        

2027

                      317        

2028

                            5,000  

2029

                             

Thereafter

    500       100                    

Total debt principal payments

    500       100       20,000       1,033       5,000  

Accrued and unpaid interest

    204       40             50       388  

Less unamortized discount and debt issuance costs

                (134 )     (20 )     (47 )

Future debt payments, net

  $ 704     $ 140     $ 19,866     $ 1,063     $ 5,341  
 

Note 9. Commitments and Contingencies

 

Commitments

 

We enter into agreements in the normal course of business with CROs for clinical trials and with vendors for preclinical studies and other services and products for operating purposes, which are cancelable at any time by us, subject to payment of our remaining obligations under binding purchase orders and, in certain cases, nominal early termination fees. These commitments are not deemed significant.

 

As of March 31, 2024 and December 31, 2023, we had commitments under various agreements for capital expenditures totaling $0.2 million and $0.4 million, respectively, related to the construction of our manufacturing facilities.

 

16

 

Contingencies

 

From time to time, we may have certain contingent legal liabilities that arise in the ordinary course of business activities. We accrue a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. We are not aware of any current material pending legal matters or claims.

 

We received the following grants from the National Multiple Sclerosis Society (“NMSS”): (i) $0.3 million in September 2019 (the “2019 Grant”) to fund biomarker research related our VISIONARY-MS Phase 2 clinical trial, and (ii) $0.7 million in May 2023 (the “2023 Grant”) to fund Cohort 2 of our REPAIR-MS clinical trial. Pursuant to the grant agreements, if we make future commercial sales of CNM-Au8 for the treatment of MS, we will repay: (i) 50% of the grants upon the first commercial product sale, (ii) an additional 50% of the grants upon cumulative sales of $10.0 million, (iii) an additional 150% of the grants upon cumulative sales of $50.0 million, and (iv) an additional 200% of the grants upon cumulative sales of $100.0 million, with the maximum repayment equal to 450% of the grants if all milestones are achieved. If NMSS has not yet received repayments equal in the aggregate to 300% of the 2019 Grant or 150% of the 2023 Grant, then upon the closing of any of the following events we will repay 300% of the 2019 Grant, equal to $1.0 million, or 150% of the 2023 Grant, equal to $1.0 million, less any amounts previously paid by us: (i) sale of all or substantially all of our assets and business, (ii) a public offering that occurs more than twelve months after completion of the applicable research, (iii) sale of any portion of our assets and business including CNM-Au8 for the treatment of MS, (iv) exclusive licensing of our intellectual property claiming CNM-Au8 for the treatment of MS, (v) a collaboration with a third-party to develop CNM-Au8 for the treatment of MS (for the 2019 Grant only), or (vi) licensing of our commercialization rights to CNM-Au8 for the treatment of MS (for the 2023 Grant only). As of March 31, 2024, we have not met any of the above milestones and the applicable research has not been completed. We accounted for these contingencies in accordance with ASC 450, Contingencies. Management has assessed the likelihood of each contingent event as less than probable and therefore no contingent liability is recognized. Management’s estimate of the possible range of loss is between the minimum and maximum repayment amounts, equal to 50% and 450% of each grant, or approximately $0.2 million and $1.5 million for the 2019 Grant, respectively; and approximately $0.3 million and $3.0 million for the 2023 Grant, respectively. However, it is at least reasonably possible that Management’s estimate of the likelihood of each contingent event and the possible range of loss will change in the near term.

 

Note 10. Income Taxes

 

The components of loss before income taxes for the three months ended March 31, 2024 and 2023 were as follows:

 

   

Three Months Ended March 31,

 

(in thousands)

 

2024

   

2023

 

United States

  $ (11,039 )   $ (11,546 )

Foreign

    (41 )     (224 )

Net loss before income taxes

  $ (11,080 )   $ (11,770 )

 

We are subject to taxation in the U.S., Australia, Netherlands, and various state jurisdictions. Our tax returns from 2017 to present are subject to examination by the U.S. and state authorities due to the carry forward of unutilized net operating losses and research and development credits. There are currently no pending examinations. We compute our quarterly income tax provision by using a forecasted annual effective tax rate and adjust for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on our net operating losses and other deferred tax assets.

 

Note 11. Benefit Plans

 

401(k) Plan

 

Our 401(k) plan is a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. We match 100% of a participating employee’s deferral contributions up to 3% of annual compensation, limited to $4,500 of matching contributions. Our contributions to the 401(k) plan totaled $0.1 million and $0.1 million for the three months ended March 31, 2024 and 2023, respectively.

 

Stock Compensation Plans

 

The Clene Nanomedicine, Inc. 2014 Stock Plan (the “2014 Plan”) was adopted in July 2014. Effective as of the closing of the Reverse Recapitalization, no additional awards may be granted under the 2014 Plan. As of March 31, 2024, 5,357,359 stock options remained outstanding under the 2014 Plan.

 

17

 

The Clene Inc. 2020 Amended Stock Plan (the “2020 Plan”) was adopted in December 2020 and amended in May 2023 and 18,400,000 shares of Common Stock are reserved for issuance thereunder. As of March 31, 2024, a total of 17,722,653 stock options and other stock awards had been granted under the 2020 Plan, and 677,347 shares remained available for future grant.

 

Stock-Based Compensation Expense

 

Stock-based compensation expense recorded in research and development expense and general and administrative expense for the three months ended March 31, 2024 and 2023 was as follows:

 

   

Three Months Ended March 31,

 

(in thousands)

 

2024

   

2023

 

General and administrative

  $ 1,136     $ 1,250  

Research and development

    877       973  

Total stock-based compensation expense

  $ 2,013     $ 2,223  

 

Stock-based compensation expense by award type for the three months ended March 31, 2024 and 2023 was as follows:

 

   

Three Months Ended March 31,

 

(in thousands)

 

2024

   

2023

 

Stock options

  $ 2,002     $ 2,222  

Stock awards

    11       1  

Total stock-based compensation expense

  $ 2,013     $ 2,223  

 

Stock Options

 

Outstanding stock options and related activity for the three months ended March 31, 2024 was as follows:

 

(in thousands, except share, per share, and term data)

 

Number of Options

    Weighted Average Exercise Price Per Share     Weighted Average Remaining Term (Years)    

Intrinsic Value

 

Outstanding – December 31, 2023

    21,846,388     $ 2.26       7.28     $ 302  

Granted

    280,070       0.44       9.95        

Forfeited

    (141,124 )     5.33              

Outstanding – March 31, 2024

    21,985,334     $ 2.22       7.07     $ 568  

Vested and exercisable – March 31, 2024

    12,511,524     $ 2.55       5.79     $ 567  

Vested, exercisable or expected to vest – March 31, 2024

    21,985,334     $ 2.22       7.07     $ 568  

 

As of March 31, 2024 and December 31, 2023, we had approximately $11.7 million and $13.7 million, respectively, of unrecognized stock-based compensation costs related to non-vested stock options which is expected to be recognized over a weighted-average period of 1.92 years and 2.10 years, respectively.

 

The weighted-average grant-date fair value of stock options granted during the three months ended March 31, 2024 and 2023 was $0.34 and $0.99, respectively. The assumptions used to calculate the fair value of stock options granted during the three months ended March 31, 2024 and 2023 were as follows:

 

  

Three Months Ended March 31,

 
  

2024

  

2023

 

Expected stock price volatility

  99.99%  96.22% –103.24%

Risk-free interest rate

  4.04%  3.38% –3.98%

Expected dividend yield

  0.00%  0.00%

Expected term of options (in years)

  5.00   5.00 –6.08 

 

18

 

Stock Awards

 

Stock awards include rights to restricted stock awards with market-based vesting conditions and restricted stock units with service-based vesting conditions. Outstanding stock awards and related activity for the three months ended March 31, 2024 was as follows:

 

    Number of Stock Awards     Weighted Average Grant Date Fair Value  

Unvested balance – December 31, 2023

    778,815     $ 9.72  

Converted to shares of Common Stock upon vesting

    (10,870 )     1.15  

Unvested balance – March 31, 2024

    767,945     $ 9.84  

 

As of March 31, 2024, we had no unrecognized stock-based compensation cost related to non-vested stock awards. As of  December 31, 2023, we had approximately $11,000 of unrecognized stock-based compensation costs related to non-vested stock awards expected to be recognized over a weighted-average period of 0.23 years.

 

Note 12. Fair Value

 

Cash, cash equivalents, and marketable securities are car